Afimetoran clinical trials
Also written BMS-986256.
How each study uses afimetoran is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the afimetoran studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
12 studies that test it; most in 2019 (3)
| Year | Studies |
|---|---|
| 2018 | 1 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 12 · Other 0
Bristol-Myers Squibb (10) · Beeline Medicines Corporation (2)
Studies
Open first, then newest update. How each study uses afimetoran is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 12
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusRecruitingPhase 2/3Beeline Medicines CorporationNCT07881120Written as Afimetoran
- A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)Active, not recruitingPhase 2Beeline Medicines CorporationNCT04895696Written as Afimetoran
- A Study to Assess the Effect of Famotidine on the Drug Levels of Afimetoran in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT05866627Written as Afimetoran
- Study to Assess the Effect of Acid-reducing Agent Famotidine on the Drug Levels of BMS-986256 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04470778Written as BMS-986256
- A Study to Assess the Effect of Phenytoin on the Drug Levels of Afimetoran and the Effect of Afimetoran on the Drug Levels of MidazolamCompletedPhase 1Bristol-Myers SquibbNCT05901714Written as Afimetoran
- A Study to Assess the Safety and Drug Levels of BMS-986256 in Participants With Active Cutaneous Lupus ErythematosusCompletedPhase 1Bristol-Myers SquibbNCT04493541Written as BMS-986256
- A Study Measuring the Effectiveness of BMS-986256 Combined With Oral Contraceptive in Healthy Female ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04016753Written as BMS-986256
- A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04941755Written as BMS-986256
- Study to Assess the Way the Body Absorbs, Distributes, Breaks Down and Eliminates Radioactive BMS-986256 in Healthy Male ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT04269356Written as BMS-986256
- Effects of BMS-986256 at Steady State on the Single Dose Pharmacokinetics of Mycophenolate MofetilCompletedPhase 1Bristol-Myers SquibbNCT04039373Written as BMS-986256
- An Investigational Study to Evaluate the Effects of Experimental Medication BMS-986256 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03634995Written as BMS-986256
- A Study to Investigate the Effects of Itraconazole on the Pharmacokinetics of BMS-986256 in Healthy ParticipantsCompletedPhase 1Bristol-Myers SquibbNCT03950960Written as BMS-986256
What changed recently
From the registry's own updates since Oct 18, 2026.
Started recruiting1
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusOct 29, 2026NCT07881120
Newly registered1
- Study of Afimetoran in Adults With Cutaneous Lupus ErythematosusOct 19, 2026NCT07881120
Codes
What other systems call afimetoran · ClinicalTrials.gg INT017219
- UNII (FDA) LXP7MZL0VFAFIMETORANOne source FDA
- NCI Thesaurus C177089AfimetoranOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | LXP7MZL0VF | AFIMETORAN | One source FDA |
| NCI Thesaurus | C177089 | Afimetoran | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.